Biblioteca

Convalescent Plasma to Treat COVID-19

Convalescent Plasma to Treat COVID-19

Tratamientos
Tema: COVID-19
Recent discovery and development of inhibitors targeting coronaviruses

Recent discovery and development of inhibitors targeting coronaviruses

Tratamientos
Tema: COVID-19
Drug treatment options for the 2019-new coronavirus (2019- nCoV)

Drug treatment options for the 2019-new coronavirus (2019- nCoV)

Tratamientos
Tema: COVID-19
Effective Treatment of Severe COVID-19 Patients with Tocilizumab

Effective Treatment of Severe COVID-19 Patients with Tocilizumab

Tratamientos
Tema: COVID-19
The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options

The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options

Tratamientos
Tema: COVID-19
The convalescent sera option for containing COVID-19

The convalescent sera option for containing COVID-19

Tratamientos
Tema: COVID-19
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Tratamientos
Tema: COVID-19
Of chloroquine and COVID-19

Of chloroquine and COVID-19

Tratamientos
Tema: COVID-19
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Tratamientos
Tema: COVID-19
Harnessing the immune system via FcγR function in immune therapy A pathway to next- gen mAbs

Harnessing the immune system via FcγR function in immune therapy A pathway to next- gen mAbs

Tratamientos
Tema: COVID-19
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Tratamientos
Tema: COVID-19
Reducing mortality from 2019-nCoV host-directed therapies should be an option

Reducing mortality from 2019-nCoV host-directed therapies should be an option

Tratamientos
Tema: COVID-19
In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus

In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus

Tratamientos
Tema: COVID-19
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

Tratamientos
Tema: COVID-19
Hydroxychloroquine and azithromycin as a treatment of COVID-19

Hydroxychloroquine and azithromycin as a treatment of COVID-19

Tratamientos
Tema: COVID-19
Clinical trials on drug repositioning for COVID-19 treatment

Clinical trials on drug repositioning for COVID-19 treatment

Tratamientos
Tema: COVID-19
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Tratamientos
Tema: COVID-19
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Tratamientos
Tema: COVID-19
Preparing for a COVID19 pandemic

Preparing for a COVID19 pandemic

Medidas preventivas
Tema: COVID-19
Taking the right measures to control COVID-19

Taking the right measures to control COVID-19

Medidas preventivas
Tema: COVID-19

Institucional

Misión y Visión de ALAT Comité Ejecutivo Estatutos y reglamentos Actividades de ALAT Sociedades Nacionales

Miembros

Beneficios Hacerme miembro

Recursos

Publicaciones Biblioteca

Contáctenos

Contacto